Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
World Neurosurg ; 133: 416-418, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31181358

RESUMEN

BACKGROUND: Brain tuberculoma is a rare manifestation of tuberculosis especially in immunosuppressed patients. The definitive diagnosis may be difficult owing to mimicking brain tumors and the absence of the common presentation. Bacille Calmette-Guérin (BCG) vaccine is used for protection against tuberculous meningitis and miliary disease, more so in children, and also for the treatment of bladder cancer. CASE DESCRIPTION: The following case of brain tuberculoma is a boy aged 6 months who was presented to our hospital with poor feeding, nausea and vomiting, and confusion lasting 1 month. A brain magnetic resonance imaging scan showed a large mass lesion in the pineal region with generalized hydrocephaly in which polymerase chain reaction assays of the tissue was positive for Mycobacterium bovis and had a good response to antituberculosis drugs and surgery. CONCLUSIONS: We present a case of brain tuberculoma as the complication of BCG vaccine. To our knowledge, this case is the first case of brain tuberculoma after BCG vaccination. We should consider brain tuberculoma that presents with a similar presentation in any infants with a history of BCG vaccination.


Asunto(s)
Antituberculosos/uso terapéutico , Vacuna BCG/efectos adversos , Infecciones por Mycobacterium/etiología , Glándula Pineal/diagnóstico por imagen , Tuberculoma Intracraneal/etiología , Humanos , Lactante , Imagen por Resonancia Magnética , Masculino , Infecciones por Mycobacterium/diagnóstico por imagen , Infecciones por Mycobacterium/tratamiento farmacológico , Mycobacterium bovis , Resultado del Tratamiento , Tuberculoma Intracraneal/diagnóstico por imagen , Tuberculoma Intracraneal/tratamiento farmacológico
2.
J Emerg Trauma Shock ; 4(3): 351-4, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21887024

RESUMEN

INTRODUCTION: Admission white blood cell (WBC) count and thrombosis in myocardial infarction (TIMI) risk score have been associated with adverse outcomes after acute myocardial infarction (AMI). This study investigated the joint effect of WBC count and TIMI risk score on predicting in-hospital outcomes in patients with AMI. MATERIALS AND METHODS: WBC count and TIMI risk score were measured at the time of hospital admission in 70 patients with AMI. Echocardiogram was done on prior to discharge by a cardiologist and ejection fraction (EF) was determined according to the Simpson formula. Patients were stratified into tertiles (low and high) based on WBC count and TIMI risk score. RESULTS: Patients with a high WBC count had a 5.0-fold increase in-hospital congestive heart failure and 2.2 increases in mortality compared with those with a low WBC count. Patients with a high TIMI risk score had a 10-fold increase in congestive heart failure presentation and mortality compared with those with a low TIMI risk score. When a combination of different strata for each variable was analyzed, a stepwise increase in mortality was seen. There were a few number of patients with a high WBC count and low TIMI risk score or with a low WBC count and high TIMI risk score. These patients had an intermediate risk, whereas those with a high WBC count and TIMI risk score had the highest risk. CONCLUSION: These findings suggested that a simple combination of WBC count and TIMI risk score might provide further information for predicting outcomes in patients with AMI.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...